

# Investor Newsletter

Issue **11** 2023






## MicroPort® CardioFlow Finishes VitaFlow Liberty® Pre-Market Implantations

Recently, the VitaFlow Liberty® Transcatheter Aortic Valve and Retrieval System (VitaFlow Liberty®), developed by MicroPort® CardioFlow, completed five pre-market implantations at Rigshospitalet (RH), Copenhagen University Hospital in Denmark.

These procedures were performed by cardiology expert Dr Ole De Backer and his team from RH, with Irish cardiology specialist Dr Darren Mylotte participating as the guiding expert. The valves were appropriately positioned in all five patients, with immediate post-operative angiography showing good valve shape and position. The surgeries were all marked successfully completed with no paravalvular leakage or regurgitation. All patients recovered well and were discharged the day after the surgery.

Dr Ole De Backer commented: “The overall release process of VitaFlow Liberty® is notably stable, ensuring precise positioning. This stability is especially crucial in patients with a small heart ventricle, where VitaFlow Liberty® consistently achieves stable and precise deployment, fully demonstrating its distinct advantages. We look forward to its positive impact on a broader patient population following CE certification.”

01





## MicroPort® MedBot™'s Toumai® Robot Finishes **First** 5G Pediatric Surgery

On October 25, MicroPort® MedBot™'s Toumai® Laparoscopic Surgical Robot (Toumai®) successfully conducted the world's first 5G Remote Pediatric Surgery from a distance of over 2000 kilometers. This groundbreaking procedure was collaboratively completed by the Shanghai National Children's Medical Center (affiliated with Shanghai Jiaotong University School of Medicine) and Sanya Women and Children's Hospital. The surgery was performed after rigorous technical demonstrations, practical experiments, and research ethics discussions.

Professor Zhaohui Lu, President of Shanghai Children's Medical Center Hainan Branch, expressed his anticipation for the normalized implementation of remote 5G medical procedures in fields including pediatrics, gynecology, and obstetrics.

Mr. Yu Liu, Executive Vice President and Chief Business Officer of MicroPort® MedBot™, stated that, "We will continue to explore 5G remote surgery applications in partnership with hospitals and surgeons, pushing forward medical technological innovation and progress and thereby enhancing the quality of healthcare and benefiting more patients."






## MicroPort EP Participates in 2023 World Congress of Arrhythmias

MicroPort EP proudly participated in the 17th World Congress of Arrhythmias (WSA), an internationally renowned conference in heart rhythm disorders, often hailed as the “Olympic event” of the field with significant influence in the industry. MicroPort EP invited experts to the quadrennial WSA for academic discussions and to showcase its innovative product portfolio.

During the meeting, Professor Yan Yao, and Dr. Emin, Dr. Can from Turkey discussed the technological advantages and clinical application experiences of the FireMagic™ TrueForce™ Ablation Catheter by sharing clinical cases and exchanging academic insights on the current state and future direction of atrial fibrillation diagnosis and treatment technologies. Dr. Emin, who recently used the FireMagic™ TrueForce™ Ablation Catheter to complete treatment procedures for two cases of atrial fibrillation and one case of atrial flutter, highly praised the device's performance.

So far, MicroPort EP's products have been exported to more than 30 countries and regions. MicroPort EP will enhance its global market presence by providing more comprehensive products and professional services for electrophysiological interventions and treatments.







## MicroPort EP Participates in **LAHRS 2023**

Recently, MicroPort EP made an appearance at the 6th Scientific Session of the Latin American Heart Rhythm Society (LAHRS 2023).

During the conference, MicroPort EP showcased its comprehensive solution for electrophysiological surgical diagnosis and treatment, which included the Columbus™ 3D EP Navigation System V3 (Columbus™ system V3), along with its accompanying FireMagic™ TrueForce™ Ablation Catheter (TrueForce™ Ablation Catheter), and other products in the series.

This exhibition marked the debut of the Columbus™ system V3 in the Latin American market. Electrophysiology experts viewed demonstration videos showcasing its magnetic and impedance-based positioning function. They also engaged in discussions about the newly CE-certified TrueForce™ Ablation Catheter and expressed their anticipation for MicroPort EP's forthcoming product offering.



# Investor Newsletter



For more information, please contact:

**Martin Sun**

Chief Financial Officer  
MicroPort Scientific Corporation

**Tel:** (86)(21) 38954600

**Email:** [ir@microport.com](mailto:ir@microport.com)

**Leanne Li**

First Vice President of Board Secretary and Legal Affairs  
MicroPort Scientific Corporation

**Tel:** (86)(21) 38954600

**Email:** [ir@microport.com](mailto:ir@microport.com)